Voyageur Pharmaceuticals Ltd.
VYYRF
$0.08
-$0.02-20.00%
OTC PK
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 290.60K | 229.10K | 373.80K | 217.10K | 162.70K |
| Depreciation & Amortization | 300.00 | 300.00 | 300.00 | 300.00 | 400.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 290.90K | 229.40K | 374.10K | 217.40K | 163.10K |
| Operating Income | -290.90K | -229.40K | -374.10K | -217.40K | -163.10K |
| Income Before Tax | -333.30K | -262.20K | -412.30K | -244.80K | -206.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -333.30K | -262.20K | -412.30K | -244.80K | -206.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -333.30K | -262.20K | -412.30K | -244.80K | -206.80K |
| EBIT | -290.90K | -229.40K | -374.10K | -217.40K | -163.10K |
| EBITDA | -290.60K | -229.10K | -373.80K | -217.10K | -162.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 139.39M | 139.45M | 138.88M | 132.74M | 132.69M |
| Average Diluted Shares Outstanding | 139.39M | 139.45M | 138.88M | 132.74M | 132.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |